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obtain consistent results, as well as including patient QOL 
evaluation to complement the clinician assessment. 
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Purpose/Objective: Adjuvant RT after quadrantectomy or 
lumpectomy plays an essential role in breast conserving 
therapy for early stage carcinoma and 60 Gy delivered in 30 
fractions in 6 weeks is generally considered the standard 
dose. The present study aims to evaluate acute, sub-acute 
and short term late side effects in patients with early stage 
breast cancer treated with adjuvant radiotherapy (RT) using 
concomitant boost. 
Materials and Methods: Between June 2010 and October 
2013, 586 patients (median age 60 years, range 27-96 years) 
with early-stage breast cancer were treated with a 
hypofractionated schedule of external beam RT after 
conserving surgery; 143 patients underwent post-operative 
chemotherapy before starting RT. RT was delivered as follow: 
45 Gy in 20 fractions (225 cGy/fr) in 4 weeks to the whole 
breast and a daily concomitant boost dose (5Gy) to the 
lumpectomy cavity (25 cGy/fr). The cumulative nominal dose 
was 50 Gy. The technique used was 3D-conformational RT 
with 2 tangential fields for the whole breast and 2 oblique 
fields for the boost. The surgical bed was primarily defined 
with clips. Toxicity was scored according to LENT-SOMA 
scale. 
Results: Twenty-five patients experienced grade 3 skin 
toxicity within one week from the end of the RT course (eight 
after adjuvant chemotherapy administered before breast 
RT).  After 19-month median follow-up (range 12-52 months), 
no grade 4 toxicity were detected; only 5 patients 
experienced grade 3 skin toxicity and thirty-nine patients 
reported grade 2 breast pain. Concerning cosmetic results, 
one patients developed scar retraction; the others 585 
patients showed excellent or good cosmetic results. Disease 
recurrences were recorded in 4 patients: one of them with 
local relapse, the others three with systemic spread.  
Conclusions: The explored regimen seems to be feasible 
providing consistent clinical results with excellent toxicity 
profile.  
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Purpose/Objective: To evaluate a mathematical model, 
based on direct tumor indicators, for target volume 
delineation of breast cancer in prone position. 
Materials and Methods: Seven patients with unifocal, early 
stage breast cancer cT1-2 cN0 were prospectively enrolled. 
Patients were installed on our breast board, applying prone 
positioning with both arms elevated above the head and an 
inclination of 10-15° towards the ipsi-lateral breast. A 
preoperative CT-scan was performed on a Toshiba® 16-slice 
CT with 100cc Visipaque® injected intravenously and using 
our standard CT-protocol (5mm slices, 120kV). Four tattoos 
were applied to reproduce positioning at the moment of 
postoperative simulation, 4 to 6 weeks later. During 
tumorectomy an 'indicator' clip (9mm) was placed in the 
cavity wall at the level of the tumor to indicate depth of the 
tumor bed. Full thickness closure was performed. The 
postoperative simulation CT (non contrast-enhanced) was 
fused with the preoperative CT, based on visual correlation. 
Delineation protocol included: 
· GTVvisual: tumor delineation based on visual CT-fusion 
· GTVvector: tumor delineation based on deformation of tumor 
volume from preoperative to postoperative CT 
· CTVmath: a ‘mathematical’ sphere with axis defined as the 
center between the indicator clip and GTVvisual centers. A 
radius of 20mm was used (Holland, Vicini), minus the minimal 
excision margin (≤10mm). Thoracic wall was subtracted from 
the resulting sphere.  
· CTVstandard: volume at risk based on indirect indicators (clips, 
seroma, tissue distortion, scar, imaging…) according to 
standard delineation guidelines 
Results: We compared volumes and location of CTVmath with 
CTVstandard and their relation to tumor GTV. 
The small CTV volumes only partially explain low Jaccard 
Index for CTVmath vs. CTVstandard (0,35 SD 0,09). Distance of 
geometrical centers varies between 9,6 to 24,5mm (mean 
14,26mm, SD 4,7) indicating a substantial difference in target 
volume localization. Tumor GTV on pre-operative CT-scan is 
more frequently included in the CTV when a mathematical 
delineation is used (overlap 0,86, SD 0,21) versus standard 
delineation (0,68, SD 0,38). No substantial difference in CTV 
volumes is observed, partly due to larger caudo-cranial 
diameter of CTVmath. Clips were often placed onto the 
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Conclusions: Replacing delineation based on guidelines by 
mathematical delineation corresponds more closely to 
microscopic spread probability, including a more systematic 
delineation of cranio-caudal tissue at risk. Deep and 
superficial clips and tissue distortion improve observer 
conformity, but do not systematically correspond to initial 
tumor location. Clips on the pectoral fascia tend to protract 
CTV unnecessarily towards the thoracic wall, thus increasing 
dose to organs at risk.  
Impact on inter-observer variation is ongoing. 
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Purpose/Objective: BRCA1 mutations contribute to about 5-
10% of breast cancer (BC) cases. The aim of the study was to 
analyze clinicopathological features, efficacy of oncological 
treatment, incidence of contralateral breast cancer (CBC) 
and other malignancies (OM) among BRCA1-positive BC 
patients (pts).  
Materials and Methods: Fifty one BRCA1-positive BC pts 
treated in Comprehensive Cancer Center in Bialystok, Poland 
between 1996 and 2010 were retrospectively analyzed. 61% 
of pts required multimodal treatment: surgery, 
chemotherapy and/or radiotherapy to breast tissue (BT), 
chest wall (CW) or regional lymph nodes (LNs) area while 
others (36.5%) were subjected only to surgical and/or 
chemotherapeutic treatment. Clinicopatological 
characteristic of pts were retrieved from clinical database. 
Results: The median age of the pts was 45.5 years (70% of pts 
were below 50). The majority of pts were at early clinical 
stage of the disease (I – 11.7%, II – 56.8%). The IIIrd stage was 
assessed in 21.6% of pts, IV – 3.9% of pts. The BRCA1 mutation 
types were 5283incC (59.5%), C61G (28.6%) and 4153 delA 
(11,9%). The negative estrogen, progesterone and HER2 
receptors status was reported in 70.3%, 74.5% and 66% of pts, 
respectively. The mastectomy was performed in 61% of pts, 
breast conserving therapy (BCT) in 35% of pts. The pts with 
metastatic disease at the time of diagnosis (3.9%) were 
treated with chemotherapy. Radiotherapy was performed on 
cobalt machine or linear accelerator with conventional 
fraction scheme. Patients were irradiated to CW – 43.7% 
(mean dose 49.8Gy) or BT – 56.3% (mean dose 49.4 Gy) 
plus/minus regional LNs – 50% (mean dose 50Gy). The mean 
treatment time accounted 35 days for pts after mastectomy 
and 45 days – after BCT. The boost was delivered by external 
beam radiotherapy in 93.8% of pts (mean dose 11.4 Gy) or by 
brachytherapy HDR – in 6,2% of pts (mean dose 10 Gy). In 
RTH-treated group regional recurrence occurred in 6.8% of 
pts who underwent mastectomy and in 5,3% of pts after BCT. 
No reoccurrence in LNs was observed in RTH group. However, 
in non-irradiated patients group, 3% developed recurrence in 
LNs and 10% of pts in CW area. With a median follow up of 
6.4 years, 13 pts (25.5%) developed distant metastases and 
11 pts (21.5%) suffered from another cancer. The most 
frequently reported malignancies were CBC (70%) and ovarian 
cancer (20%). Skin, coli uteri and parotid gland cancers were 
also observed. The LR recurrence or OM were not reported 
among pts with 4153 delA mutation. 
Conclusions: Breast cancer in BRCA1 carriers represents 
mostly negative status of steroid or HER2 receptors and is 
locally advanced at the time of diagnosis. Unfortunately, 
locoregional relapse or other malignancies are observed 
among this subset of pts. What is interesting, pts with 4153 
delA mutation did not demonstrate any adverse events. 
Identification of predictive factors is necessary to estimate 
the individual risk of developing LR recurrence or other 
cancers in BRCA1 carriers. Better understanding of 
correlations between type of BRCA1 mutations and treatment 
results is necessary for creating patients-directed approach. 
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Purpose/Objective: There are radiobilogical reasons 
justifying the use of hypofracctionation in breast cancer. 
Since the α/ß value of breast cancer has been estimated 
around 4 Gy, high fraction doses may be more efficient. 
However, this doses may also increase the frequency and 
severity of side effects in normal tissues. IMRT has the 
potential to improve target coverage and reduce 
inhomogeneities observed within the breast (and regional 
lymph nodes) and enables dose reduction to normal 
structures with the potential to reduce treatment toxicity 
improving cosmesis. According to the results published of 
phase III trials that compared standard treatment versus 
hypofractionated treatments, we started a hypofractionation 
protocol with Volumetric arc therapy (VMAT) with 
simultaneous boost to the tumor bed in those patients at high 
risk of local recurrence . The purpose of the study is to 
communicate the preliminary results in 40 patients treated in 
2013-2014. 
Materials and Methods: Inclusion criteria: left breast, 
irregular chest wall, prophylactic irradiation of 
supraclavicular area, voluminous breast and patient desire. 
 Treatment Protocol: 
· Targets: PTV1: mamary gland or anterior chest wall. PTV2: 
ipsilateral supraclavicular area. PTV3: tumor bed. 
· Dose and prescription: PTV1 and PTV2: 42,56 Gy (2,66 
Gy/fr). PTV3: 46,4 Gy (2,9 Gy/fr). 
· OAR constraints: contralateral breast: Dmax < 5 Gy; spinal 
cord: Dmax < 40 Gy; lung : V20 < 10 %, V10 < 20 %; coronary 
artery/ heart: V30 < 30 %; esophagus: Dmax < 40 Gy; thyroid: 
Dmax < 40 Gy. 
· Treatment planing system: Monaco 3.3 using Monte Carlo 
dose calculation algorithm. 
· Technique: tangencials arcs for breast and boost, and a 
semiarc for supraclavicular fold. 
